FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1980672928> ?p ?o ?g. }

• W1980672928 endingPage "395" @default.
• W1980672928 startingPage "391" @default.
• W1980672928 abstract "We present the rationale and design for MARQUEE, a phase III, randomized, double-blind, placebo-controlled study of ARQ 197 plus erlotinib versus placebo plus erlotinib in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer (NSCLC). The design of MARQUEE is based on preclinical data, the current understanding of the role of cellular N-methyl-N'-nitroso-guanidine human osteosarcoma (MNNG HOS) transforming gene (MET) in NSCLC, and clinical data from a randomized phase II study. The available evidence suggests that dual inhibition of MET and the epidermal growth factor receptor (EGFR) may overcome resistance to EGFR inhibitors. In the phase II study, the combination of tivantinib plus erlotinib significantly improved progression-free survival (PFS) and overall survival (OS) compared with placebo plus erlotinib in the subset of patients with nonsquamous histology, a population enriched for MET overexpression. The primary endpoint in MARQUEE is OS. Secondary and exploratory objectives include determination of PFS, OS in molecular subgroups (defined by EGFR and KRAS mutation status, amplification or overexpression of MET, and serum hepatocyte growth factor), and safety. All patients will be tested for biomarkers, and the results will provide a wealth of information on the role of tivantinib in treating nonsquamous NSCLC." @default.
• W1980672928 created "2016-06-24" @default.
• W1980672928 creator A5001428569 @default.
• W1980672928 creator A5013979917 @default.
• W1980672928 creator A5026119562 @default.
• W1980672928 creator A5030914311 @default.
• W1980672928 creator A5043397424 @default.
• W1980672928 creator A5045588447 @default.
• W1980672928 creator A5050185260 @default.
• W1980672928 creator A5075333926 @default.
• W1980672928 creator A5078389632 @default.
• W1980672928 creator A5079802303 @default.
• W1980672928 date "2012-09-01" @default.
• W1980672928 modified "2023-10-16" @default.
• W1980672928 title "Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer" @default.
• W1980672928 cites W1973978070 @default.
• W1980672928 cites W1974894259 @default.
• W1980672928 cites W1994912526 @default.
• W1980672928 cites W1998971866 @default.
• W1980672928 cites W2042278676 @default.
• W1980672928 cites W2056187710 @default.
• W1980672928 cites W2077224394 @default.
• W1980672928 cites W2093613683 @default.
• W1980672928 cites W2097574458 @default.
• W1980672928 cites W2099725888 @default.
• W1980672928 cites W2120795894 @default.
• W1980672928 cites W2138309116 @default.
• W1980672928 cites W2140126391 @default.
• W1980672928 cites W2145835533 @default.
• W1980672928 cites W2320909702 @default.
• W1980672928 doi "https://doi.org/10.1016/j.cllc.2012.01.003" @default.
• W1980672928 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22440336" @default.
• W1980672928 hasPublicationYear "2012" @default.
• W1980672928 type Work @default.
• W1980672928 sameAs 1980672928 @default.
• W1980672928 citedByCount "127" @default.
• W1980672928 countsByYear W19806729282012 @default.
• W1980672928 countsByYear W19806729282013 @default.
• W1980672928 countsByYear W19806729282014 @default.
• W1980672928 countsByYear W19806729282015 @default.
• W1980672928 countsByYear W19806729282016 @default.
• W1980672928 countsByYear W19806729282017 @default.
• W1980672928 countsByYear W19806729282018 @default.
• W1980672928 countsByYear W19806729282019 @default.
• W1980672928 countsByYear W19806729282020 @default.
• W1980672928 countsByYear W19806729282022 @default.
• W1980672928 countsByYear W19806729282023 @default.
• W1980672928 crossrefType "journal-article" @default.
• W1980672928 hasAuthorship W1980672928A5001428569 @default.
• W1980672928 hasAuthorship W1980672928A5013979917 @default.
• W1980672928 hasAuthorship W1980672928A5026119562 @default.
• W1980672928 hasAuthorship W1980672928A5030914311 @default.
• W1980672928 hasAuthorship W1980672928A5043397424 @default.
• W1980672928 hasAuthorship W1980672928A5045588447 @default.
• W1980672928 hasAuthorship W1980672928A5050185260 @default.
• W1980672928 hasAuthorship W1980672928A5075333926 @default.
• W1980672928 hasAuthorship W1980672928A5078389632 @default.
• W1980672928 hasAuthorship W1980672928A5079802303 @default.
• W1980672928 hasConcept C121608353 @default.
• W1980672928 hasConcept C126322002 @default.
• W1980672928 hasConcept C142724271 @default.
• W1980672928 hasConcept C143998085 @default.
• W1980672928 hasConcept C203092338 @default.
• W1980672928 hasConcept C204787440 @default.
• W1980672928 hasConcept C27081682 @default.
• W1980672928 hasConcept C2776256026 @default.
• W1980672928 hasConcept C2778087573 @default.
• W1980672928 hasConcept C2779177807 @default.
• W1980672928 hasConcept C2779438470 @default.
• W1980672928 hasConcept C2781187634 @default.
• W1980672928 hasConcept C2908647359 @default.
• W1980672928 hasConcept C2909325608 @default.
• W1980672928 hasConcept C31760486 @default.
• W1980672928 hasConcept C526805850 @default.
• W1980672928 hasConcept C535046627 @default.
• W1980672928 hasConcept C71924100 @default.
• W1980672928 hasConcept C81729549 @default.
• W1980672928 hasConcept C98274493 @default.
• W1980672928 hasConcept C99454951 @default.
• W1980672928 hasConceptScore W1980672928C121608353 @default.
• W1980672928 hasConceptScore W1980672928C126322002 @default.
• W1980672928 hasConceptScore W1980672928C142724271 @default.
• W1980672928 hasConceptScore W1980672928C143998085 @default.
• W1980672928 hasConceptScore W1980672928C203092338 @default.
• W1980672928 hasConceptScore W1980672928C204787440 @default.
• W1980672928 hasConceptScore W1980672928C27081682 @default.
• W1980672928 hasConceptScore W1980672928C2776256026 @default.
• W1980672928 hasConceptScore W1980672928C2778087573 @default.
• W1980672928 hasConceptScore W1980672928C2779177807 @default.
• W1980672928 hasConceptScore W1980672928C2779438470 @default.
• W1980672928 hasConceptScore W1980672928C2781187634 @default.
• W1980672928 hasConceptScore W1980672928C2908647359 @default.
• W1980672928 hasConceptScore W1980672928C2909325608 @default.
• W1980672928 hasConceptScore W1980672928C31760486 @default.
• W1980672928 hasConceptScore W1980672928C526805850 @default.
• W1980672928 hasConceptScore W1980672928C535046627 @default.
• W1980672928 hasConceptScore W1980672928C71924100 @default.
• W1980672928 hasConceptScore W1980672928C81729549 @default.

• next